Why carry out this study?

Historically, improvements in lung function and exacerbation reduction have been the focus of trials to assess new treatments for COPD

However, the need to assess the impact of COPD symptoms on patient health-related quality of life is also important

This article provides additional evidence of improvements in patient-reported outcomes within the InforMing the PAthway of COPD Treatment (IMPACT; NCT02164513) study in patients with symptomatic COPD and a history of exacerbations

What was learned from the study?

Clinically meaningful improvements in patient-reported outcomes favored FF/UMEC/VI over FF/VI or UMEC/VI for the treatment of patients with symptomatic COPD at risk of exacerbations

Treatment of patients with symptomatic COPD at risk of exacerbations with FF/UMEC/VI improves patient-perceived health-related quality of life and symptoms compared with FF/VI or UMEC/VI